Physician profile
Abid I Khan
NPI 1932288735
$625,922.21
in general payments reported to CMS, 2019-2025
9 companies · $204K in 2025
The $204K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148K · 2020: $48K · 2021: $58K · 2022: $56K · 2023: $55K · 2024: $57K · 2025: $204K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $226K · Consulting Fee: $46K · Travel and Lodging: $36K · Food and Beverage: $8,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $226,379.00 |
| Consulting Fee | $46,075.00 |
| Travel and Lodging | $35,652.81 |
| Food and Beverage | $8,376.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $290,694.48 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $151,445.73 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $147,088.88 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $20,431.07 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15,561.27 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $530.66 | 2019-2025 | Invega Sustenna |
| Lundbeck LLC | $128.72 | 2019-2024 | Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $24.25 | 2019 | |
| Neurocrine Biosciences, INC. | $17.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.